Please login to the form below

Not currently logged in
Email:
Password:

Humira still the biggest pharma brand

The industry’s best-selling products revealed in the latest PMLiVE Top Pharma List figures
Humira - Abbott

AbbVie's flagship brand Humira continued its stellar performance last year to retain the top spot in the PMLiVE Top Pharma List ranking of the industry's 50 biggest products.

The ranking, produced exclusively for PMLiVE by GlobalData, showed Humira (adalimumab) powered its way to the top of the 2013 chart on the back of sales that grew 20 per cent to $11.5bn.

Described early on in its life as a 'pipeline in a product' by its manufacturer, due to its potential in multiple lucrative indications, Humira's recent performance was assisted by new uses in areas such as ulcerative colitis and psoriasis.

The rheumatoid arthritis drug managed once again to keep at bay two of its fellow anti-TNF inhibitors, Johnson & Johnson's Remicade (infliximab) and Pfizer/Amgen's Enbrel (etanercept).

It also means that once again all of the top three products were biologic treatments, a category that is expected to show continued growth.

Elsewhere in the Top Pharma List's latest product rankings there was confirmation of strong performance from Sanofi's Lantus (insulin glargine), sales of which grew 15 per cent to $7.3bn last year.

Double-digit sales growth was also seen from Pfizer's fibromyalgia drug Lyrica (pregabalin), which GlobalData said made sales of $4.8bn in 2013, in the process overtaking Lipitor to become Pfizer's best-selling product.

The once-mighty cholesterol brand has been in free fall since it began to go off-patent in 2011 and generic competition had already cut a swathe through Lipitor's 2012 sales, which were reduced by more than half to $4.8bn. The decline was slightly less pronounced in 2013, but sales were still down by about a third to $3.1bn.

Visit the full PMLiVE Top Pharma List. It includes rankings of the 25 biggest companies and the full top 50 products ranking

Article by
Dominic Tyer

9th April 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics